EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring the Other Side of Medication: A Patient Interview Study on Anti‐PCSK9 Monoclonal Antibodies

Ting Zhang, Doudou Li, Yanmei Ning, Jiana Shi, Ying Hu iD

Cardiovascular Therapeutics · 2026-01 · 2026 (1)

DOI: 10.1155/cdr/8814045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Therapeutics, online erschienen am 16.06.2026. Verfasst von Ting Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Clinical Pharmacy Center, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hang…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Medication Adherence, PCSK9 Inhibitors, Serine Proteinase Inhibitors. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: second batch of undergraduate provincial-level teaching reform record projects in the 14th Five-Year Plan, Zhejiang Yangtze River Delta Health Science Research Fund Project, Zhejiang Medical and Health Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors demonstrate significant lipid‐lowering effects, but the widespread use of anti‐PCSK9 monoclonal antibodies remains limited.

Purpose

This study is aimed at understanding patients′ real‐world experiences with anti‐PCSK9 monoclonal antibodies from a subjective perspective and identifying key factors influencing medication adherence.

Methods

A qualitative research methodology was employed, involving face‐to‐face semistructured in‐depth interviews with 24 individuals who had previously used anti‐PCSK9 monoclonal antibodies. The interviews were guided by a thematic framework approach and recorded in their entirety. Posttranscription, Colaizzi′s phenomenological analysis method was utilized to systematically collect and interpret patient‐reported subjective experiences.

Results

Among those continuing treatment, the most common motivating factors were the anti‐PCSK9 monoclonal antibodies′ favorable efficacy and fewer adverse reactions. Among those discontinuing treatment, the primary reasons for stopping were high medication costs (62.5%), insufficient recognition of the necessity for continued use (62.5%), and unwillingness to use injection administration (68.75%). The underlying determinants of patients′ behavioral patterns can be elucidated and mitigated by applying the health belief model and the theory of planned behavior.

Conclusion

Research findings indicate that patients′ willingness to use medication is primarily influenced by three factors: perceived good efficacy, health awareness, and fear of needles and economic burden. We are aimed at enhancing long‐term clinical benefits for patients and improving treatment adherence, establishing education about drug efficacy and necessity, promoting innovation of nasal spray or long‐acting implant formulations, and achieving precise medical insurance coverage for high‐risk populations. Trial Registration ChiCTR registration number: ChiCTR2500101339

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalMedication AdherencePCSK9 InhibitorsSerine Proteinase InhibitorsAnticholesteremic AgentsDyslipidemiasHumansFemaleMiddle AgedMaleHealth Knowledge, Attitudes, PracticeTreatment OutcomeProprotein Convertase 9Qualitative ResearchAgedInterviews as TopicDrug CostsAdultMotivation

Stichwörter der Autor:innen

Colaizzi analysis methodanti-PCSK9 monoclonal antibodiesqualitative studytreatment adherence

Substanzen

Antibodies, MonoclonalPCSK9 protein, humanProprotein Convertase 9PCSK9 InhibitorsSerine Proteinase InhibitorsAnticholesteremic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Clinical Pharmacy Center, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China, hznu.edu.cn.
  • School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China, hznu.edu.cn.

ORCID-Profile: Ying Hu

Förderung

  • second batch of undergraduate provincial-level teaching reform record projects in the 14th Five-Year Plan
  • Zhejiang Yangtze River Delta Health Science Research Fund Project
  • Zhejiang Medical and Health Science and Technology
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, T., Li, D., Ning, Y., Shi, J., & Hu, Y. (2026). Exploring the Other Side of Medication: A Patient Interview Study on Anti‐PCSK9 Monoclonal Antibodies. Cardiovascular Therapeutics, 2026(1). https://doi.org/10.1155/cdr/8814045

Vancouver

Zhang T, Li D, Ning Y, Shi J, Hu Y. Exploring the Other Side of Medication: A Patient Interview Study on Anti‐PCSK9 Monoclonal Antibodies. Cardiovascular Therapeutics. 2026;2026(1). doi:10.1155/cdr/8814045

BibTeX
@article{Zhang2026,
  author = {Zhang, Ting and Li, Doudou and Ning, Yanmei and Shi, Jiana and Hu, Ying},
  title = {Exploring the Other Side of Medication: A Patient Interview Study on Anti‐PCSK9 Monoclonal Antibodies},
  journal = {Cardiovascular Therapeutics},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/cdr/8814045}
}
Kostenlos starten →